PSMA6 and benign prostatic hyperplasia: The implications were that combination therapy of HSE and alpha-1 blockers for moderate LUTS/BPH subjects might be an effective strategy for preserving their sexual function, especially having higher BMI and/or metabolic syndrome disorders [157].